{"id":"serdolect","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL12713","moleculeType":"Small molecule","molecularWeight":"440.95"},"aliases":["sertindole"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 6, D(4) dopamine receptor"},"_scrapedAt":"2026-03-28T04:25:40.120Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Schizophrenia","diseaseId":"schizophrenia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01498770","phase":"","title":"An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-04-01","conditions":"Bipolar Disorder","enrollment":42},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":"Schizophrenia","enrollment":174},{"nctId":"NCT02021201","phase":"PHASE4","title":"The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia","status":"TERMINATED","sponsor":"Birte Glenthoj","startDate":"2008-07","conditions":"Schizophrenia","enrollment":1},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":"Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders","enrollment":21},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00763438","phase":"PHASE4","title":"Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2007-11","conditions":"Schizophrenia","enrollment":18},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":"Psychosis Nos/Other","enrollment":104},{"nctId":"NCT00654706","phase":"PHASE3","title":"Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2008-03","conditions":"Schizophrenia, Cognition","enrollment":264},{"nctId":"NCT00864045","phase":"PHASE3","title":"Sertindole in Asian Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2007-03","conditions":"Schizophrenia","enrollment":394},{"nctId":"NCT00759460","phase":"PHASE3","title":"Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2007-03","conditions":"Schizophrenia","enrollment":250},{"nctId":"NCT00759421","phase":"PHASE3","title":"Exploratory Cognition Study of Sertindole in Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2006-10","conditions":"Schizophrenia","enrollment":96},{"nctId":"NCT00885690","phase":"NA","title":"Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)","status":"TERMINATED","sponsor":"University of Aarhus","startDate":"2009-04","conditions":"Schizophrenia","enrollment":11},{"nctId":"NCT00629252","phase":"NA","title":"The Effect of Sertindole on Sensory Gating and Cognition in Schizophrenic Patients","status":"TERMINATED","sponsor":"University of Zurich","startDate":"2008-02","conditions":"Schizophrenia","enrollment":14},{"nctId":"NCT00612079","phase":"NA","title":"The Effect of Sertindole on Sensory Gating and Cognition in Healthy Volunteers","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2007-09","conditions":"Healthy","enrollment":30},{"nctId":"NCT00856583","phase":"PHASE3","title":"Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2002-07","conditions":"Schizophrenia","enrollment":9809},{"nctId":"NCT00345982","phase":"NA","title":"Augmenting Clozapine With Sertindole - SERCLOZ","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2006-09","conditions":"Schizophrenia","enrollment":50},{"nctId":"NCT00480844","phase":"PHASE4","title":"Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2008-10","conditions":"Schizophrenia","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":14,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_1","status":"active","brandName":"Serdolect","genericName":"Serdolect","companyName":"University of Aarhus","companyId":"university-of-aarhus","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sertindole, sold under the brand name Serdolect, is an antipsychotic medication used in the treatment of schizophrenia. It works as a dopamine D2 receptor antagonist, a small molecule that blocks the action of dopamine at these receptors in the brain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}